Medytox, first quarter operating profit increased by 35%... improving profitability despite a decrease in sales revenue

Medytox saw growth in operating profit and net profit in the first quarter of this year, with profitability improving. Although sales declined versus the same period last year, profit figures instead improved due to factors such as cost-efficiency initiatives and changes in product mix.

On the 12th, Medytox disclosed in an announcement that, based on consolidated financial statements, its operating profit for the first quarter of 2026 was 7.4 billion South Korean won. This represents a 34.6% increase compared with the same period last year. Sales in the same period were 60.7 billion South Korean won, down 5.1% year over year, but net profit was 7.9 billion South Korean won, up sharply by 135.7% year over year.

A decline in sales alongside an increase in operating profit can generally be understood as not simply reflecting an expansion in scale, but rather an actual increase in retained earnings. Operating profit is the figure remaining after deducting costs and major expenses such as sales and administrative expenses from product sales revenue, making it a representative indicator of how much a company’s core business capabilities are improving. Net profit also rose significantly, ultimately indicating that its profitability improved compared with the same period last year.

Medytox is a KOSDAQ-listed company, and changes in its performance are one of the important benchmarks investors use to assess the growth potential and stability of biotech firms. In particular, in the biotech industry—where R&D and sales structures differ—quarterly earnings volatility is often high. As a result, not only sales scale but also the quality of profits are given equal weight.

This trend could become a standard for judging whether Medytox will continue to operate its business in the future with profitability at the center. Going forward, whether the decline in sales is temporary or reflects changes in the business environment will determine the sustainability of the improved performance, which is expected to become a key focus for the market.